122 related articles for article (PubMed ID: 37558530)
1. Utilization of Serial Next-Generation Sequencing Among Patients Receiving CPX-351 for Newly Diagnosed Acute Myeloid Leukemia.
Jain AG; Ball S; Aguirre LE; Tobon KA; Chan O; Padron E; Kuykendall A; Komrokji R; Sallman D; Lancet JE; Sweet K
Clin Lymphoma Myeloma Leuk; 2023 Oct; 23(10):e315-e322. PubMed ID: 37558530
[TBL] [Abstract][Full Text] [Related]
2. The characteristics and clinical prognosis analysis of ASXL1 mutations in Chinese adult patients with primary cytogenetically normal acute myeloid leukemia by next-generation sequencing.
Xu J; Hao Z; Chen X; Hong M; Muyey DM; Chen X; Wang H
Leuk Lymphoma; 2022 Oct; 63(10):2321-2329. PubMed ID: 35652795
[TBL] [Abstract][Full Text] [Related]
3. Impact of the variant allele frequency of ASXL1, DNMT3A, JAK2, TET2, TP53, and NPM1 on the outcomes of patients with newly diagnosed acute myeloid leukemia.
Sasaki K; Kanagal-Shamanna R; Montalban-Bravo G; Assi R; Jabbour E; Ravandi F; Kadia T; Pierce S; Takahashi K; Nogueras Gonzalez G; Patel K; Soltysiak KA; Cortes J; Kantarjian HM; Garcia-Manero G
Cancer; 2020 Feb; 126(4):765-774. PubMed ID: 31742675
[TBL] [Abstract][Full Text] [Related]
4. Gene mutation analysis using next-generation sequencing and its clinical significance in patients with myeloid neoplasm: A multi-center study from China.
Li J; Pei L; Liang S; Xu S; Wang Y; Wang X; Liao Y; Zhan Q; Cheng W; Yang Z; Tang X; Zhang H; Xiao Q; Chen J; Liu L; Wang L
Cancer Med; 2023 Apr; 12(8):9332-9350. PubMed ID: 36799265
[TBL] [Abstract][Full Text] [Related]
5. Multicolor Flow Cytometry and Multigene Next-Generation Sequencing Are Complementary and Highly Predictive for Relapse in Acute Myeloid Leukemia after Allogeneic Transplantation.
Getta BM; Devlin SM; Levine RL; Arcila ME; Mohanty AS; Zehir A; Tallman MS; Giralt SA; Roshal M
Biol Blood Marrow Transplant; 2017 Jul; 23(7):1064-1071. PubMed ID: 28315400
[TBL] [Abstract][Full Text] [Related]
6. [Using next generation sequencing technology to analyze gene mutations in patients with acute myeloid leukemia and the impact on prognosis].
Zhao CX; Wang JM; Li JM; Zou SH; Chen FY; Liang AB; Hou J; Hu XX; Zhang YX; Gu SY; Zhu JY; Li P; Du J; Yang YN; Qin YW; Wang XR; Wang C
Zhonghua Yi Xue Za Zhi; 2019 Oct; 99(40):3145-3151. PubMed ID: 31694105
[No Abstract] [Full Text] [Related]
7. Characteristics and prognostic significance of genetic mutations in acute myeloid leukemia based on a targeted next-generation sequencing technique.
Wang RQ; Chen CJ; Jing Y; Qin JY; Li Y; Chen GF; Zhou W; Li YH; Wang J; Li DW; Zhao HM; Wang BH; Wang LL; Wang H; Wang MZ; Gao XN; Yu L
Cancer Med; 2020 Nov; 9(22):8457-8467. PubMed ID: 32970934
[TBL] [Abstract][Full Text] [Related]
8. Next-generation sequencing of acute myeloid leukemia identifies the significance of TP53, U2AF1, ASXL1, and TET2 mutations.
Ohgami RS; Ma L; Merker JD; Gotlib JR; Schrijver I; Zehnder JL; Arber DA
Mod Pathol; 2015 May; 28(5):706-14. PubMed ID: 25412851
[TBL] [Abstract][Full Text] [Related]
9. Persistence of DNMT3A R882 mutations during remission does not adversely affect outcomes of patients with acute myeloid leukaemia.
Bhatnagar B; Eisfeld AK; Nicolet D; Mrózek K; Blachly JS; Orwick S; Lucas DM; Kohlschmidt J; Blum W; Kolitz JE; Stone RM; Bloomfield CD; Byrd JC
Br J Haematol; 2016 Oct; 175(2):226-236. PubMed ID: 27476855
[TBL] [Abstract][Full Text] [Related]
10. Genomic Mutation Profiles of Patients with Acute Myeloid Leukemia in Korea: a Single-Center Experience.
Han E; Ryu S; Kim D; Koh EH; Byun JH; Lee DH
Clin Lab; 2023 Nov; 69(11):. PubMed ID: 37948498
[TBL] [Abstract][Full Text] [Related]
11. Gene mutation profile and risk stratification in AML1‑ETO‑positive acute myeloid leukemia based on next‑generation sequencing.
Yu G; Yin C; Wu F; Jiang L; Zheng Z; Xu D; Zhou J; Jiang X; Liu Q; Meng F
Oncol Rep; 2019 Dec; 42(6):2333-2344. PubMed ID: 31638252
[TBL] [Abstract][Full Text] [Related]
12. [Clinical features and survival analysis in non-M(3) acute myeloid leukemia patients with ASXL1 gene mutation].
Jia WB; Liu JT; Yang XY; Wu HY; Wei YH; Can C; Wang RQ; He N; Gu CY; Ma DX; Ji CY
Zhonghua Xue Ye Xue Za Zhi; 2022 Oct; 43(10):833-840. PubMed ID: 36709197
[No Abstract] [Full Text] [Related]
13. Comparison of mutational profiles and clinical outcomes in patients with acute myeloid leukemia with mutated
Nguyen L; Zhang X; Roberts E; Yun S; McGraw K; Abraham I; Song J; Braswell D; Qin D; Sallman DA; Lancet JE; List AF; Moscinski LC; Padron E; Zhang L
Leuk Lymphoma; 2020 Jun; 61(6):1395-1405. PubMed ID: 32091281
[TBL] [Abstract][Full Text] [Related]
14. FLT3-ITD Compared with DNMT3A R882 Mutation Is a More Powerful Independent Inferior Prognostic Factor in Adult Acute Myeloid Leukemia Patients After Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Cohort Study.
Ardestani MT; Kazemi A; Chahardouli B; Mohammadi S; Nikbakht M; Rostami S; Jalili M; Vaezi M; Alimoghaddam K; Ghavamzadeh A
Turk J Haematol; 2018 Aug; 35(3):158-167. PubMed ID: 29786546
[TBL] [Abstract][Full Text] [Related]
15. Correlation Analysis and Prognostic Impacts of Biological Characteristics in Elderly Patients with Acute Myeloid Leukemia.
Li F; Li N; Wang A; Liu X
Clin Interv Aging; 2022; 17():1187-1197. PubMed ID: 35967966
[TBL] [Abstract][Full Text] [Related]
16. Next-generation sequencing reveals gene mutations landscape and clonal evolution in patients with acute myeloid leukemia.
Chen X; Zhu H; Qiao C; Zhao S; Liu L; Wang Y; Jin H; Qian S; Wu Y
Hematology; 2021 Dec; 26(1):111-122. PubMed ID: 33491606
[TBL] [Abstract][Full Text] [Related]
17. Identification of relapse-associated gene mutations by next-generation sequencing in low-risk acute myeloid leukaemia patients.
Prieto-Conde MI; Jiménez C; García-Álvarez M; Ramos F; Medina A; Cuello R; Balanzategui A; Alonso JM; Sarasquete ME; Queizán JA; Alcoceba M; Bárez A; Puig N; Cantalapiedra A; Gutiérrez NC; García-Sanz R; González-Díaz M; Chillón MC
Br J Haematol; 2020 May; 189(4):718-730. PubMed ID: 32124426
[TBL] [Abstract][Full Text] [Related]
18. Mutation clonal burden and allogeneic hematopoietic cell transplantation outcomes in acute myeloid leukemia and myelodysplastic syndromes.
Hamilton BK; Rybicki L; Hirsch C; Przychodzen B; Nazha A; Gerds AT; Hanna R; Kalaycio M; Sekeres MA; Sobecks R; de Lima M; Majhail NS; Maciejewski J
Bone Marrow Transplant; 2019 Aug; 54(8):1281-1286. PubMed ID: 30655603
[TBL] [Abstract][Full Text] [Related]
19. Genomic characteristics and prognostic significance of co-mutated ASXL1/SRSF2 acute myeloid leukemia.
Richardson DR; Swoboda DM; Moore DT; Johnson SM; Chan O; Galeotti J; Esparza S; Hussaini MO; Van Deventer H; Foster MC; Coombs CC; Montgomery ND; Sallman DA; Zeidner JF
Am J Hematol; 2021 Apr; 96(4):462-470. PubMed ID: 33502020
[TBL] [Abstract][Full Text] [Related]
20. IDH1/2 but not DNMT3A mutations are suitable targets for minimal residual disease monitoring in acute myeloid leukemia patients: a study by the Acute Leukemia French Association.
Debarri H; Lebon D; Roumier C; Cheok M; Marceau-Renaut A; Nibourel O; Geffroy S; Helevaut N; Rousselot P; Gruson B; Gardin C; Chretien ML; Sebda S; Figeac M; Berthon C; Quesnel B; Boissel N; Castaigne S; Dombret H; Renneville A; Preudhomme C
Oncotarget; 2015 Dec; 6(39):42345-53. PubMed ID: 26486081
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]